These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31647951)

  • 41. Evaluation of Nanoparticle Tracking Analysis for the Detection of Rod-Shaped Particles and Protein Aggregates.
    Hoover BM; Murphy RM
    J Pharm Sci; 2020 Jan; 109(1):452-463. PubMed ID: 31604086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors Governing the Precision of Subvisible Particle Measurement Methods - A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe.
    Ríos Quiroz A; Lamerz J; Da Cunha T; Boillon A; Adler M; Finkler C; Huwyler J; Schmidt R; Mahler HC; Koulov AV
    Pharm Res; 2016 Feb; 33(2):450-61. PubMed ID: 26474763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors.
    Vlieland ND; Nejadnik MR; Gardarsdottir H; Romeijn S; Sediq AS; Bouvy ML; Egberts ACG; van den Bemt BJF; Jiskoot W
    Pharm Res; 2018 Feb; 35(2):42. PubMed ID: 29404710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Introducing the Alba
    Chillon A; Pace A; Zuccato D
    PDA J Pharm Sci Technol; 2018; 72(4):382-392. PubMed ID: 29853611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Characterization Laboratory.
    Caputo F; Mehn D; Clogston JD; Rösslein M; Prina-Mello A; Borgos SE; Gioria S; Calzolai L
    J Chromatogr A; 2021 Jan; 1635():461767. PubMed ID: 33310281
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Taking Subvisible Particle Quantitation to the Limit: Uncertainties and Statistical Challenges With Ophthalmic Products for Intravitreal Injection.
    Gühlke M; Hecht J; Böhrer A; Hawe A; Nikels F; Garidel P; Menzen T
    J Pharm Sci; 2020 Jan; 109(1):505-514. PubMed ID: 31682829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein Nanoparticles Promote Microparticle Formation in Intravenous Immunoglobulin Solutions During Freeze-Thawing and Agitation Stresses.
    Pardeshi NN; Zhou C; Randolph TW; Carpenter JF
    J Pharm Sci; 2018 Jul; 107(7):1852-1857. PubMed ID: 29601840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Issues and challenges of subvisible and submicron particulate analysis in protein solutions.
    Scherer TM; Leung S; Owyang L; Shire SJ
    AAPS J; 2012 Jun; 14(2):236-43. PubMed ID: 22391789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preparation of submicron drug particles via spray drying from organic solvents.
    Dobrowolski A; Strob R; Dräger-Gillessen JF; Pieloth D; Schaldach G; Wiggers H; Thommes M
    Int J Pharm; 2019 Aug; 567():118501. PubMed ID: 31288055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overview of drug product development.
    Narayan P
    Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.
    Anzengruber J; Lubich C; Prenninger T; Gringeri A; Scheiflinger F; Reipert BM; Malisauskas M
    J Thromb Haemost; 2018 Jun; 16(6):1176-1181. PubMed ID: 29665242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity.
    Caputo F; Clogston J; Calzolai L; Rösslein M; Prina-Mello A
    J Control Release; 2019 Apr; 299():31-43. PubMed ID: 30797868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A critical review of analytical methods for subvisible and visible particles.
    Narhi LO; Jiang Y; Cao S; Benedek K; Shnek D
    Curr Pharm Biotechnol; 2009 Jun; 10(4):373-81. PubMed ID: 19519412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overcoming Challenges of Implementing Closed System Transfer Device Clinical In-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates.
    Petoskey F; Kwok SC; Jackson W; Jiang S
    J Pharm Sci; 2020 Jan; 109(1):761-768. PubMed ID: 31376374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging techniques for submicrometer particle sizing applied to Stöber silica.
    Bell NC; Minelli C; Tompkins J; Stevens MM; Shard AG
    Langmuir; 2012 Jul; 28(29):10860-72. PubMed ID: 22724385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fundamentals of freeze-drying.
    Nail SL; Jiang S; Chongprasert S; Knopp SA
    Pharm Biotechnol; 2002; 14():281-360. PubMed ID: 12189727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of particle size methodology and assessment of nanoparticle tracking analysis (NTA) as a tool for live monitoring of crystallisation pathways.
    McComiskey KPM; Tajber L
    Eur J Pharm Biopharm; 2018 Sep; 130():314-326. PubMed ID: 30012404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein-polyelectrolyte interactions: Monitoring particle formation and growth by nanoparticle tracking analysis and flow imaging microscopy.
    Sediq AS; Nejadnik MR; El Bialy I; Witkamp GJ; Jiskoot W
    Eur J Pharm Biopharm; 2015 Jun; 93():339-45. PubMed ID: 25936855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.